Dizhe Pharmaceutical (688192.SH): A number of research results in the field of lung cancer were selected for the 2026 American Society of Clinical Oncology (ASCO) Conference Report

Zhitong Finance App News, Dizhe Pharmaceutical (688192.SH) announced the latest research results of its self-developed products Schwarzhe® (generic name: sulvortinib tablets), and DZD6008 in the field of non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) annual meeting to be held in Chicago from May 29 to June 2, 2026.

At the 2026 ASCO conference, the research results of the Schwarzer® international multi-center phase III clinical study “Wukong 28” (WU KONG28) were selected as the latest breakthrough summary (LBA) oral report, becoming the world's first and only drug selected for LBA in the field of epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon20ins) NSCLC treatment.

Schwarzer® is an oral, irreversible, and highly selective EGFR tyrosine kinase inhibitor (TKI) for various EGFR mutation subtypes. It can effectively cover various EGFR mutation subtypes, including classical driving mutations and refractory mutations (exon20ins and PACC mutations). It is currently the only oral targeted drug in the world that has been approved by both China and the US and is covered by medical insurance.

At the same time, DZD6008's latest clinical study on patients with EGFRC797X mutant NSCLC will also be presented at this conference in the form of an oral report. As a new, highly selective, fourth-generation EGFRTKI that completely penetrates the blood-brain barrier, DZD6008 aims to fill unmet clinical needs after three generations of EGFRTKI resistance. Previous studies have shown that DZD6008 has shown significant anti-tumor activity and good safety for carrying a variety of EGFR mutations, including sensitive mutations (L858r/19del), drug-resistant double mutations (L858R/19DEL and T790M/C797x), or triple mutations (L858r/19del, T790M, and C797X).

In addition, at the conference, the company will also announce the latest research progress on a first-line treatment of NSCLC without driving gene mutations using Gaorizhe® combined with anti-PD-1 antibodies. Gao Ruizhe® is the world's first and only highly selective JAK1 inhibitor approved for T-cell lymphoma. Preclinical studies have shown that JAK inhibitors reverse T-cell depletion, improve the tumor immune microenvironment, and combined immunotherapy can potentially reverse PD-1 inhibitor resistance, providing a mechanistic basis for GaoRuizhe® combined anti-PD1/PD-L1 treatment.